Sonoma Pharmaceuticals, Inc. 8-K

What Happened

• Sonoma Pharmaceuticals, Inc. (SNOA) filed a Form 8-K reporting that on April 8, 2026 it entered into a Manufacturing and Supply Agreement with Kenvue Brands LLC for the sale of Microcyn® technology‑based products in the United States.
• The agreement is effective as of October 24, 2025 and runs through March 2027, with the option to extend for up to two additional one‑year terms by mutual written agreement. The company filed a copy of the agreement as Exhibit 10.1, with certain portions redacted for confidentiality.

Key Details

• Agreement entered: April 8, 2026; effective date: October 24, 2025.
• Initial term: through March 2027; potential extensions: up to two one‑year terms upon mutual consent.
• Product scope: Microcyn® technology‑based products for sale in the United States.
• Financial terms and some schedules/exhibits were omitted from the public filing; Sonoma will furnish omitted material to the SEC upon request.

Why It Matters

• This agreement formalizes a commercial manufacturing/supply relationship with Kenvue, which could support U.S. distribution and potential revenue from Microcyn‑based products. However, the filing does not disclose pricing, volumes, or other financial terms, so investors cannot yet gauge the deal’s revenue or profit impact. Sonoma’s 8-K also contains standard forward‑looking statement disclosures; investors should watch for future filings or company updates that provide financial details or commercialization milestones.